

Special Issue

Extracellular Vesicles as Future Therapeutics and Indicators of Cardiac Disease

Message from the Guest Editors

Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. Extracellular vesicles have attracted significant attention in mediating intercellular communication during cardiovascular development and pathophysiology. Exosomal ncRNAs, including microRNAs, lncRNAs, and circRNAs, are considered to be key players, offering a potential source of novel diagnostic and prognostic biomarkers for CVDs. This Special Issue aims to highlight the novel studies and strategies that might overcome current obstacles in cardiovascular translational medicine and their potential applications. Specific themes we would like contributors to address include, but are not limited to:

- Extracellular vesicles in cardiac cells differentiation;
- Extracellular vesicles in cardiovascular repair and regeneration;
- Extracellular vesicles in cardiovascular protection;
- Extracellular vesicles in cardiovascular drug development and safety assay;
- Extracellular vesicles in tissue engineering;
- Extracellular vesicles in CVD diagnostic and prognostic;
- Extracellular vesicles in CVD pathogenesis;
- Extracellular vesicles in cardiovascular homeostasis.

Guest Editors

Dr. Jiacheng Sun

Dr. Junjie Yang

Dr. Yu-An Lu

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/147565

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).